HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit

Executive Summary

Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)
Advertisement

Related Content

Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
Drug-Eluting Stent Payment Based On U.K. Price Sets Precedent – MedPAC
Drug-Eluting Stent Payment Based On U.K. Price Sets Precedent – MedPAC
J&J Eprex Stability Improvements Planned In Response To Aplasia Incidence
Aranesp Oncology Costs: “Exorbitant” (J&J); “Very Competitive” (Amgen)
Advertisement
UsernamePublicRestriction

Register

PS040507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel